Smart Inhalers Market by Product (Inhalers and Nebulizers, Dry Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs)), Indication (Asthma and COPD), End User (Patients and R and D) - Global Opportunity Analysis and Industry Forecast, 2014 - 2022

  • ID: 3934618
  • Report
  • Region: Global
  • 202 pages
  • Allied Analytics LLP
1 of 5

FEATURED COMPANIES

  • Adherium Limited
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Cohero Health, LLC
  • GlaxoSmithKline plc
  • Novartis AG
  • MORE
Smart inhalers are clip-on sensors, also known as connected inhalers, which are attached to the traditional inhalers. They are used to track the medication, dosage, and time taken for each dose. Linked wirelessly to the cloud, smart inhalers are a part of “Internet of Things,” thus providing correct use of the medication, improved adherence to the inhaler, and better health outcomes. Doctors and patients can easily benefit from the use of smart inhalers as they monitor the dosage and provide reminders at the time of the dose, which can be recorded for understanding the patient’s daily routine.

The world smart inhalers market is analyzed under three different scenarios, namely, moderate growth, rapid growth, and diminishing growth. Under the moderate growth scenario, smart inhalers market is estimated to reach $191 million by 2022, growing at a CAGR of 63.3% during 2016 to 2022. Market growth is attributed to the rapid increase in the incidence of respiratory diseases, rise in air pollution, and growth in healthcare burden, due to higher cases of asthma and COPD. In addition, expected increase in adherence to smart inhalers is another major factor for the growth of smart inhalers market. However, limited availability of smart inhalers, high cost of asthma and COPD treatment, and resistance towards adoption of smart inhalers are expected to hinder the market growth.

The market is segmented on the basis of product, indication, end user, and geography. By product, it is segmented into inhalers and nebulizers. Inhalers dominates the market, which is further divided into dry powder inhalers (DPIs) and metered dose inhalers (MDIs). Based on indication, smart inhalers are bifurcated into asthma and COPD. On the basis of end user, it is divided into patients and R&D. In terms of geography, the market is analyzed into North America, Europe, Asia-Pacific, and LAMEA.

North America was the leading revenue-generating region, whereas Asia-Pacific is projected to grow at the highest CAGR of 65.3%, owing to rise in demand for smart inhalers and increase in COPD and asthma cases.

Companies have adopted product approval and clinical trials as their key development strategies. Increase in focus on clinical trials is mainly for the development of innovative technologies in the field of smart inhalers. In March 2016, Adherium received a product approval to sell its “SmartTurbo” and “SmartTouch” devices in Canada, thereby expanding its product portfolio.

Key players operating in the market include:

Adherium Limited
Teva Pharmaceutical Industries Ltd. (Gecko Health Innovations)
Propeller Health
Cohero Health, LLC
OPKO Health, Inc. (Inspiro Medical Ltd.)
GlaxoSmithKline plc
Novartis AG
AstraZeneca plc
Boehringer Ingelheim GmbH
Vectura Group plc

KEY BENEFITS FOR STAKEHOLDERS:

The report provides an in-depth analysis of the estimated revenues generated by smart inhalers as well as major geographies during the forecast period.
The report presents three different market scenarios for smart inhalers, both for value and volume, based on rapid growth, diminishing growth, and moderate growth scenarios.
Quantitative analysis of the current market and estimations from 2016 to 2022 is presented to help the manufacturers of smart inhalers to analyze the market.
Entire projections presented in the report highlight the market potential, both in terms of value and volume.
The report conducts extensive analysis of the market by closely following key product positioning and monitoring the top contenders within the market framework.

Key market segments:

By Product

Inhalers
Dry Powder Inhalers (DPIs)
Metered Dose Inhalers (MDIs)
Nebulizers
By Indication

Asthma
COPD

BY END USER

Patients
R&D

BY GEOGRAPHY

North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
UAE
Rest of LAMEA
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adherium Limited
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Cohero Health, LLC
  • GlaxoSmithKline plc
  • Novartis AG
  • MORE
CHAPTER 1 INTRODUCTION

1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments
1.4 Research Methodology

1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Analyst Tools and Models

CHAPTER 2 EXECUTIVE SUMMARY

2.1 CXO Perspective

CHAPTER 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Key Findings

3.2.1 Top Winning Strategies
3.2.2 Top Investment Pockets

3.3 Porters Five Forces Analysis

3.3.1 Bargaining Power of Suppliers
3.3.2 Bargaining Power of Buyers
3.3.3 Threat of Substitutes
3.3.4 Threat of New Entrants
3.3.5 Intensity of Competitive Rivalry

3.4 Top Player Positioning, 2015
3.5 Clinical Trials
3.6 Product Portfolio
3.7 Market Dynamics

3.7.1 Drivers

3.7.1.1 Global increase in air pollution
3.7.1.2 Increase in population susceptible to indoor air pollutants
3.7.1.3 Increasing prevalence of COPD and asthma globally
3.7.1.4 Expected increase in adherence to smart inhalers
3.7.1.5 Increasing collaboration between pharmaceutical companies and smart inhaler manufacturers
3.7.1.6 Rising incidences of chronic conditions

3.7.2 Restraints

3.7.2.1 Misusing data and data privacy
3.7.2.2 Availability of smart inhalers
3.7.2.3 Overall high cost of asthma and COPD treatment
3.7.2.4 Resistance towards adoption of smart inhalers

3.7.3 Opportunities

3.7.3.1 Increased focus towards advanced treatment protocols
3.7.3.2 Significant unmet need in respiratory care
3.7.3.3 Increased awareness to reduce healthcare costs
3.7.3.4 Opportunities in emerging economies

CHAPTER 4 SMART INHALERS MARKET, BY PRODUCT, 2014-2022

4.1 Overview

4.1.1 Market Size and Forecast

4.2 Inhalers

4.2.1 Key Market Trends
4.2.2 Growth Factors and Opportunities
4.2.3 Market Size and Forecast
4.2.4 Dry Powder Inhalers (DPIs)
4.2.5 Metered Dose Inhalers (MDIs)

4.3 Nebulizers

4.3.1 Key Market Trends
4.3.2 Growth Factors and Opportunities
4.3.3 Market Size and Forecast

CHAPTER 5 SMART INHALERS MARKET, BY INDICATION, 2014-2022

5.1 Overview

5.1.1 Market Size and Forecast

5.2 Asthma

5.2.1 Market Size and Forecast

5.3 COPD

5.3.1 Market Size and Forecast

CHAPTER 6 SMART INHALERS MARKET, BY END USER, 2014-2022

6.1 Overview

6.1.1 Market Size and Forecast

6.2 Patients

6.2.1 Market Size and Forecast

6.3 R&D

6.3.1 Market Size and Forecast

CHAPTER 7 SMART INHALERS MARKET, BY GEOGRAPHY, 2014-2022

7.1 Overview

7.1.1 Market Size and Forecast

7.2 North America

7.2.1 Key Market Trends
7.2.2 Growth Factors and Opportunities
7.2.3 Market Size and Forecast

7.2.3.1 U.S.: Market Size and Forecast
7.2.3.2 Canada: Market Size and Forecast
7.2.3.3 Mexico: Market Size and Forecast

7.3 Europe

7.3.1 Key Market Trends
7.3.2 Growth Factors and Opportunities
7.3.3 Market Size and Forecast

7.3.3.1 Germany: Market Size and Forecast
7.3.3.2 UK: Market Size and Forecast
7.3.3.3 France: Market Size and Forecast
7.3.3.4 Italy: Market Size and Forecast
7.3.3.5 Russia: Market Size and Forecast

7.4 Asia-Pacific

7.4.1 Key Market Trends
7.4.2 Growth Factors and Opportunities
7.4.3 Market Size and Forecast

7.4.3.1 Japan: Market Size and Forecast
7.4.3.2 China: Market Size and Forecast
7.4.3.3 India: Market Size and Forecast
7.4.3.4 Australia: Market Size and Forecast
7.4.3.5 Rest of Asia-Pacific: Market Size and Forecast

7.5 LAMEA (Latin America, Middle East, and Africa)

7.5.1 Key Market Trends
7.5.2 Growth Factors and Opportunities
7.5.3 Market Size and Forecast

7.5.3.1 Brazil: Market Size and Forecast
7.5.3.2 Turkey: Market Size and Forecast
7.5.3.3 Saudi Arabia: Market Size and Forecast
7.5.3.4 UAE: Market Size and Forecast
7.5.3.5 Rest of Lamea: Market Size and Forecast

CHAPTER 8 COMPANY PROFILES

8.1 Adherium Limited

8.1.1 Company Overview
8.1.2 Company Snapshot
8.1.3 Operating Business Segments
8.1.4 Business Performance
8.1.5 Key Strategic Moves and Developments

8.2 Teva Pharmaceutical Industries Ltd. (Gecko Health Innovations)

8.2.1 Company Overview
8.2.2 Company Snapshot
8.2.3 Operating Business Segments
8.2.4 Business Performance
8.2.5 Key Strategic Moves and Developments

8.3 Propeller Health

8.3.1 Company Overview
8.3.2 Company Snapshot
8.3.3 Operating Business Segments
8.3.4 Business Performance
8.3.5 Key Strategic Moves and Developments

8.4 Cohero Health, LLC

8.4.1 Company Overview
8.4.2 Company Snapshot
8.4.3 Operating Business Segments
8.4.4 Business Performance
8.4.5 Key Strategic Moves and Developments

8.5 OPKO Health, Inc. (Inspiro Medical Ltd.)

8.5.1 Company Overview
8.5.2 Company Snapshot
8.5.3 Operating Business Segments
8.5.4 Business Performance
8.5.5 Key Strategic Moves and Developments

8.6 GlaxoSmithKline plc

8.6.1 Company Overview
8.6.2 Operating Business Segments
8.6.3 Business Performance
8.6.4 Key Strategic Moves and Developments

8.7 Novartis AG

8.7.1 Company Overview
8.7.2 Operating Business Segments
8.7.3 Business Performance
8.7.4 Key Strategic Moves and Developments

8.8 AstraZeneca plc

8.8.1 Company Overview
8.8.2 Operating Business Segments
8.8.3 Business Performance
8.8.4 Key Strategic Moves and Developments

8.9 Boehringer Ingelheim GmbH

8.9.1 Company Overview
8.9.2 Operating Business Segments
8.9.3 Business Performance
8.9.4 Key Strategic Moves and Developments

8.10 Vectura Group plc

8.10.1 Company Overview
8.10.2 Company Snapshot
8.10.3 Operating Business Segments
8.10.4 Business Performance
8.10.5 Key Strategic Moves and Developments
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Adherium Limited
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Cohero Health, LLC
  • GlaxoSmithKline plc
  • Novartis AG
  • MORE
A new report, "Smart Inhalers Market by Product, Indication, and End User -Global Opportunity Analysis and Industry Forecast, 2014 -2022",states that the global smart inhalers market was $5.8 million in 2015 and is expected to reach $191 million by 2022, growing at a CAGR of 63.3% from 2016 to 2022. The inhalers segment captured majority share in 2015, whereas nebulizers segment is projected to grow at fastest CAGR of 64.1% during the forecast period. North America, which accounted for around two-fifths share in 2015, is expected to maintain its lead throughout.

Smart inhalers promote adherence to inhalers and also send timely reminders to patients to take their inhaler dose at the required time due to which it has emerged as a novel approach in asthma and COPD management. The major factors that drives the smart inhalers market include worldwide growth in population susceptible to indoor air pollutants, inclination of patients towards digitalized medical devices for monitoring daily medication doses, and rise in prevalence of asthma and COPD. In addition, improved smart inhalers adherence rate and increase in collaboration between pharmaceutical companies and smart inhaler manufacturers promotes technological advancements which would ultimately support the market growth. These smart inhalers directly transfer medication data to the mobile application as well as to the cloud server connected through the internet. Thus, assuring doctor on exact medicine intake and frequency of the same. However, data privacy and limited availability of smart inhalers across regions acts as a major limitation in the market growth.

Smart inhaler products comprise sensors that can be easily attached on the traditional inhalers and nebulizers. The inhalers segment accounted for major share of the overall market, as inhalers are preferred as first option of treatment, portability, and cost effectiveness leading to volume sales. However, nebulizers are expected to grow at the fastest rate due to technological advancements that result in their portability and ease of use.

North America accounted for the majority of the revenue in 2015 owing to the increased adoption of smart inhalers and increased awareness about asthma and COPD treatment. Asia-Pacific is projected to be the fastest growing region throughout the analysis period with major revenue contribution from China. Improvement in healthcare infrastructure and increase in healthcare expenditure in the emerging markets (such as India and China) is projected to fulfill the unmet medical needs thus, fueling the smart inhalers market growth in the Asia-Pacific region.

Key findings of the smart inhalers market study:

In the year 2015, inhalers led the global smart inhalers market revenue, and is projected to grow at a CAGR of 63.2%.
Smart inhalers market for asthma is expected to grow at a CAGR of 62.0%, in terms of revenue, whereas for COPD, is expected to grow at a CAGR of 64.5%.
COPD indication segment is expected to grow at a CAGR of 64.5% due to increase in COPD incidence rate, rise in adherence rate.
The majority of smart inhalers are used by R&D centers and this trend is expected to be continued during the forecast period.
Europe and Asia-Pacific together accounted for around half of the market share in 2015.
China is the major shareholder, accounting for about one-third share of the Asia-Pacific smart inhalers market, in terms of value.
U.S. smart inhalers market is expected to grow at a CAGR of 59.5%.
German smart inhalers market is expected to grow at a CAGR of 68.2% during analysis period.
Recent developments such as acquisition of Inspiro Medical by Opko Health, collaboration between Novartis and Qualcomm, and acquisition of Gecko Health by Teva pharmaceuticals for manufacturing smart inhalers further signify the increase in competition in the smart inhalers industry. These developments are majorly focused on manufacturing smart inhalers as well as launching new devices with inbuilt smart inhalers instead of using an add on sensor to the device; thereby positively increasing the market revenue as well as competition among the manufacturers.

Major players profiled in this report include Vectura Group plc, Adherium Limited, Teva Pharmaceutical Industries Ltd. (Gecko Health Innovations), AstraZeneca plc, Propeller Health, Cohero Health, LLC, Boehringer Ingelheim GmbH, OPKO Health, Inc. (Inspiro Medical Ltd.), GlaxoSmithKline plc, and Novartis AG.
Note: Product cover images may vary from those shown
5 of 5
Adherium Limited
Teva Pharmaceutical Industries Ltd. (Gecko Health Innovations)
Propeller Health
Cohero Health, LLC
OPKO Health, Inc. (Inspiro Medical Ltd.)
GlaxoSmithKline plc
Novartis AG
AstraZeneca plc
Boehringer Ingelheim GmbH
Vectura Group plc
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll